 Cortexyme, Inc. Nasdaq: CRTX, a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimers and other degenerative diseases, today announced new data supporting the ability of the pathogen Porphyromonas gingivalis to invade brain cells and trigger characteristic Alzheimers pathology including synaptic loss, ultrastructural changes, and inflammation. The data is being presented this week as part of the Advances in Alzheimers and Parkinsons Disease AAT-ADPD Focus Meeting 2020, which was converted to a virtual meeting due to the COVID-19 pandemic and is being held April 2-5. 